KPC(SH:600422)2016-10-27 16:00Financial Performance - Operating revenue for the first nine months rose by 7.38% to CNY 3,570,183,061.20 compared to the same period last year[6]. - Net profit attributable to shareholders increased by 6.16% to CNY 330,418,097.99 compared to the same period last year[6]. - Total operating revenue for Q3 2016 was CNY 1,070,195,536.50, a decrease of 5.8% compared to CNY 1,136,255,437.52 in Q3 2015[28]. - Total comprehensive income for the first nine months of 2016 was approximately CNY 299.68 million, compared to CNY 268.92 million in the same period last year, representing an increase of 11.4%[34]. - The total profit for Q3 2016 was ¥82,571,678.64, an increase from ¥76,178,534.95 in Q3 2015[33]. Assets and Liabilities - Total assets increased by 3.33% to CNY 5,113,069,900.35 compared to the end of the previous year[6]. - Total liabilities decreased to CNY 711,378,723.71 from CNY 748,842,249.85 at the start of the year, reflecting a reduction of approximately 5.5%[27]. - The company's equity increased to CNY 3,202,525,943.03, compared to CNY 3,064,530,757.47 at the beginning of the year, marking a growth of about 4.5%[27]. Cash Flow - Net cash flow from operating activities decreased by 49.26% to CNY 155,520,170.73 compared to the same period last year[6]. - Cash inflow from operating activities for the first nine months was CNY 3.73 billion, up from CNY 3.29 billion year-on-year, indicating a growth of 13.4%[36]. - Cash inflow from investment activities was CNY 2.89 billion, significantly higher than CNY 810.03 million in the previous year, marking an increase of 256.5%[37]. - The net cash flow from financing activities was negative at CNY 157.90 million, compared to a positive flow of CNY 163.29 million in the previous year[39]. Shareholder Information - Total number of shareholders reached 34,590[11]. - The largest shareholder, Huafang Pharmaceutical Technology Co., Ltd., holds 29.79% of shares, totaling 234,928,716 shares[11]. - Other major shareholders include Yunnan Hehe (Group) Co., Ltd. with 7.61% and Yunnan Provincial Industrial Investment Holding Group Co., Ltd. with 2.16%[11]. Expenses and Investments - Development expenses increased by 28.03% to ¥123,682,241.75, reflecting higher investment in drug research and development[12]. - Sales expenses for Q3 2016 were ¥118,515,158.74, a decrease of 23.3% from ¥154,570,088.10 in Q3 2015[33]. - Investment income for Q3 2016 was ¥7,728,604.51, significantly higher than ¥1,189,400.26 in Q3 2015[33]. Earnings and Dividends - Basic earnings per share decreased by 8.18% to CNY 0.4189 compared to the same period last year[6]. - The company plans to maintain a minimum cash dividend payout ratio of 30% of distributable profits[16]. - The company reported a basic earnings per share of CNY 0.23 for the first nine months, reflecting a stable performance compared to the previous year[34].